NCT04802876 2025-03-21ACROPOLISOLTI Breast Cancer Research GroupPhase 2 Active not recruiting184 enrolled
NCT04866836 2025-03-21A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant TumorsThe First Affiliated Hospital with Nanjing Medical UniversityPhase 2 Terminated20 enrolled
NCT04672434 2024-12-09Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor MalignanciesSymphogen A/SPhase 1 Completed48 enrolled
NCT04641871 2024-06-26Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor MalignanciesSymphogen A/SPhase 1 Completed78 enrolled
NCT03779100 2019-01-28Lenvatinib Plus PD-1 Antibody for Unresectable ICCSun Yat-sen UniversityPhase 2 Suspended25 enrolled